INSY Insys Therapeutics, Inc.

10.51
+0  (1%)
Previous Close 10.36
Open 10.41
Price To book 2.76
Market Cap 756.27M
Shares 71,957,000
Volume 345,933
Short Ratio 8.22
Av. Daily Volume 931,452

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved January 5, 2012.
SUBSYS
Cancer pain
Phase 2 initiated August 2016
Pharmaceutical Cannabidiol (CBD)
Cocaine dependence
Announced approval July 5, 2016.
Dronabinol Oral Solution
AIDS-related anorexia
Phase 2 enrollment initiated February 2016
Pharmaceutical Cannabidiol (CBD)
Infantile spasms (IS)
Phase 3 planned.
Cannabidiol
Epilepsy
Phase 3 data met primary endpoints - August 2016
Buprenorphine
Moderate to severe postoperative pain after bunionectomy
Dose ranging trial to be initiated 1H 2015, with Phase 3 to be initiated 2H 2015. Data due 2016.
Subsys
Acute post-operative pain

Latest News

  1. Insys Therapeutics to Report First Quarter 2017 Results on May 9, 2017
  2. EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Filed in U.S. District Court to Recover Losses Suffered by Investors in INSYS Therapeutics, Inc.
  3. Dr. Steven James Joins Insys Therapeutics as Vice President of Medical Affairs
  4. Better Know a Marijuana Stock: Insys Therapeutics
  5. SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against INSYS Therapeutics, Inc. (INSY) and Lead Plaintiff Deadline: May 16, 2017
  6. ETFs with exposure to INSYS Therapeutics, Inc. : April 20, 2017
  7. INSY EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of INSYS Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 16, 2017 - INSY
  8. SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in INSYS Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - INSY
  9. INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Has Filed in U.S. District Court to Recover Losses Suffered by Investors in INSYS Therapeutics, Inc.
  10. One company symbolizes everything sickening about the opioid crisis
  11. Biotech Movers Trading Positive Ahead of Market's Open
  12. INSYS Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : INSY-US : April 11, 2017
  13. The Klein Law Firm Announces the Filing of a Class Action on Behalf of INSYS Therapeutics, Inc. Shareholders and a Lead Plaintiff Deadline of May 16, 2017
  14. 5 Drug-Developing Marijuana Stocks You Need to Know
  15. The Klein Law Firm Announces a Class Action Filed on Behalf of INSYS Therapeutics, Inc. Shareholders and a Lead Plaintiff Deadline of May 16, 2017
  16. EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Insys Therapeutics, Inc. – INSY
  17. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against INSYS Therapeutics, Inc. (INSY) & Lead Plaintiff Deadline: May 16, 2017